CAS No. 2641216-67-1
Batch:
Purity:98.17
Chemical Structure
Check the
Calderasib (MK-1084)
product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.
| IUPAC Name | 19-chloro-22-(2,5-dimethyl-4-prop-2-enoylpiperazin-1-yl)-13,16-difluoro-3-propan-2-yl-8,11-dioxa-1,4,23,26-tetrazapentacyclo[16.6.2.02,7.012,17.021,25]hexacosa-2(7),3,5,12,14,16,18,20,22,25-decaen-24-one | |
|---|---|---|
| CAS Number | 2641216-67-1 | |
| Molecular Formula |
C32H31ClF2N6O4 |
|
| Molecular Weight (MW) | 637.08 | |
| SMILES | FC1=C2C(OCCOC3=CC=NC(C(C)C)=C3N4C5=NC2=C(Cl)C=C5C(N6[C@@H](C)CN(C(C=C)=O)[C@H](C)C6)=NC4=O)=C(F)C=C1 | |
| InChIKey | BBIVCWWQPMOKAC-UHFFFAOYSA-N |
Calderasib (MK-1084) is a potent and selective macrocyclic covalent inhibitor targeting mutant KRAS G12C. By covalently binding to the switch II pocket of GDP-bound KRAS G12C, it suppresses downstream RAS/RAF/MEK/ERK signaling pathway activation, thereby blocking cancer cell proliferation and suppressing tumor growth. Furthermore, calderasib exhibits robust antitumor efficacy both as a monotherapy and in combination with immune checkpoint inhibitors such as pembrolizumab in KRAS G12C-driven oncology models. [1]
|
Concentration
Volume
Mass
|
|---|
Batch:
All in vitro solubility values are batch-tested experimental data (non-literature values).
| Solvent | Solubility & Note |
|---|---|
| DMSO |
100 mg/mL
(156.96 mM)
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO. The recommended stock concentration is 10 mM in DMSO.) |
| Ethanol | 100 mg/mL |
| Water | Insoluble |
| DMSO |
100 mg/mL
(156.96 mM)
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO. The recommended stock concentration is 10 mM in DMSO.) |
| Ethanol | 25 mg/mL |
| Water | Insoluble |
Q: Why does a DMSO stock precipitate in media/saline?
A: It is caused by unheated aqueous media (supersaturation), local solvent shock, or incorrect mixing sequence.
How to fix it?
- Preheat media/saline to 37°C.
- Mix rapidly (pipette/vortex) upon addition.
- For complex mixes, always add the aqueous phase last.
- Re-dissolve minor precipitates with a 37°C water bath and sonication (≤30 min).
- Calderasib (MK-1084) Clinical Trials
- Calderasib (MK-1084) Solubility in DMSO
- Calderasib (MK-1084) Stock Solution
- Calderasib (MK-1084) Storage
- Calderasib (MK-1084) Stability
- Calderasib (MK-1084) Molecular Weight
- Calderasib (MK-1084) SMILES
- Calderasib (MK-1084) Chemical Structure (2D and 3D)
- Calderasib (MK-1084) SDS|MSDS
Note: Technical data last updated: Sep 1, 2026.